Risk Factor Modification, Prevention, and Stroke Prevention in AFib (On - Demand)-Risk Factor Modification, Prevention, and Stroke Prevention in AFib (Video)

Video Transcription

Video Summary

In the HRS online town hall, Peter Noseworthy from Mayo Clinic discussed atrial fibrillation (AFib) management with Rakesh Gopinathan Nair and Janice Chu, focusing on lifestyle modifications and stroke prevention. Janice emphasized the significant paradigm shift in the 2023 guidelines prioritizing lifestyle risk factor modifications as a key pillar in AFib management. The guidelines now prescribe detailed recommendations for primary and secondary AFib prevention through managing comorbidities like obesity, hypertension, and diabetes, alongside lifestyle changes such as weight loss, increased physical activity, smoking cessation, and alcohol moderation.<br /><br />Rakesh elaborated on updates in stroke prevention, noting a shift away from using a single risk scoring system. Instead, annual percentage stroke risks are emphasized. Novel guidelines highlight the use of other scoring models like ATRIA and GARFIELD for a comprehensive risk assessment and recommend anticoagulation for those with a 2% or higher annual risk. Furthermore, the guidelines have improved recommendations for left atrial appendage occlusion as an anticoagulant alternative.<br /><br />Both speakers agreed on the necessity for individualized, patient-centered approaches to encourage lifestyle changes, emphasizing the role of technology in facilitating integrated care. Looking ahead, they anticipate further developments in risk assessment, treatment of subclinical AFib, and technological advancements enhancing AFib management. They also discussed ongoing studies that might alter the therapeutic landscape, highlighting an evolving understanding and treatment paradigm for AFib.

Keywords

atrial fibrillation

AFib management

lifestyle modifications

stroke prevention

2023 guidelines

risk assessment

anticoagulation

patient-centered care

technology in healthcare

therapeutic advancements